Akinsanya Karen 4

What Happened
Karen Akinsanya — President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrodinger (SDGR) — sold 1,366 shares on 2026-03-05 in an open market/broker-assisted sale. The weighted-average price was $12.90, for total proceeds of approximately $17,625. The sale was effected under a durable Rule 10b5-1 automatic sale instruction and was to satisfy tax withholding related to the vesting of restricted stock units (RSUs); it was not a discretionary trade.

Key Details

• Date: 2026-03-05 (Form 4 filed 2026-03-06 — appears timely).
• Transaction: Sale (S) of 1,366 shares; weighted-average price $12.90; price range $12.71–$13.00. Total proceeds ≈ $17,625.
• Purpose/footnotes: Broker-assisted sale under a 10b5-1 plan to cover RSU withholding (F1). Price is a weighted average across multiple executions (F2).
• Holdings note: Footnote indicates inclusion of 63,545 unvested RSUs (F3). The filing does not state an exact total of shares owned after this tax-withholding sale.

Context
Sales executed under 10b5-1 plans or to satisfy tax withholding on RSU vesting are typically routine and do not necessarily signal insider sentiment about the company. For retail investors, purchases by insiders tend to carry more informational weight than routine withholding sales.